Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.
Research and practice in thrombosis and haemostasis
View this publicationResearch and practice in thrombosis and haemostasis
View this publicationNMR in biomedicine
View this publicationThe Lancet. Respiratory medicine
View this publicationClinical research in cardiology : official journal of the German Cardiac Society
View this publicationCirculation. Cardiovascular interventions
View this publicationNature
View this publicationCirculation. Cardiovascular interventions
View this publicationJournal of affective disorders
View this publicationAmerican journal of respiratory and critical care medicine
View this publicationJournal of clinical medicine
View this publication